Ayers Gilberth Ivano Kalaij

Mrs. Ayers Gilberth Ivano Kalaij

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2021 in Asia Pacific Journal of Public Health
Verified
Journal Article
Closed access
PDF file
AKAyers Gilberth Ivano Kalaij
Ayers Gilberth Ivano Kalaij
MSMichael Sugiyanto
Michael Sugiyanto
AIAhmad Fadhil Ilham
Ahmad Fadhil Ilham
Although vaccination coverage has reached a peak of 86% globally, around 19.9 million infants and children are yet to receive routine vaccinations—with Asia holding the highest prevalence of noncompliance. This implies notable gaps in vaccination coverage among some regions in the world. This study aims to analyze the factors associated with compliance toward childhood vaccination in Southeast Asia. A systematic review of observational studies was conducted using the following databases: PubMed, Scopus, and Cochrane. Included studies analyze factors affecting compliance with childhood vaccination in Southeast Asia, and assessed with Joanna Briggs Institute (JBI) and Newcastle-Ottawa Scale’s criteria. Sixteen observational studies were included, with a total of 41 956 subjects, consisting of 15 cross-sectional studies and one case-control study. Our results suggested that parental personal–related, children and family status–related, socioeconomic, and health care–related factors strongly affected subjects’ compliance with immunization. Prominent determinants were older maternal age, higher economics groups, parents in government or health care sectors, and frequent antenatal care visits. On the other hand, noncompliance were associated with younger age, large quantity of family members, lower economic groups, lower education, and unemployed parents. We hope that this comprehensive assessment thoroughly addresses challenges and inform strategies to raise compliance toward childhood vaccination in Southeast Asia.

15 July 2024 in Public Health Challenges
Verified
Journal Article
Open access
RSRisyad Abiyyu Siregar
Risyad Abiyyu Siregar
FQFona Qorina
Fona Qorina
AKAyers Gilberth Ivano Kalaij
Ayers Gilberth Ivano Kalaij
HAHera Afidjati
Hera Afidjati
DLDhani Latifani
Dhani Latifani
AMAzizah Salsabila Mahmud
Azizah Salsabila Mahmud
Indonesia is grappling with a rise in obesity and diabetes, partially driven by a high consumption of sugar‐sweetened beverages. The prevalence of obesity among adults more than doubled from 2007 to 2018, and diabetes rates have also increased. In response, the Indonesian government has proposed an excise tax on sugar‐sweetened beverages to reduce consumption. However, the implementation of this policy has repeatedly been delayed, with the latest postponement to 2024. Sugar‐sweetened beverages contribute significantly to chronic diseases, increasing the healthcare burden and reducing economic productivity. Taxation, a widely used public health strategy in the form of fiscal measures, can decrease consumption by raising prices, raising public awareness, encouraging product reformulation, and generating revenue. Despite its potential benefits, the proposed tax in Indonesia faces substantial political and commercial challenges. The president‐elect Prabowo Subanto has not explicitly supported the tax in his political manifesto, raising concerns about further delays due to industry lobbying. Successful implementation of the tax requires robust political will, public and civil society pressure, and effective cross‐sector cooperation. The government must ensure clear policy goals, equal application to domestic and foreign products, and supportive measures such as providing free drinking water alternatives. Transparent stakeholder consultations can build broad‐based support, whereas effective monitoring and evaluation frameworks are essential for compliance. To gain public support, allocating tax revenues to public health and social programs is crucial. Although initial resistance is expected, strong enforcement mechanisms can ensure adherence. With determined political commitment and public advocacy, the sugar‐sweetened beverage tax can significantly reduce obesity and diabetes rates, improving public health outcomes and economic productivity in Indonesia. This commentary provides an overview of the proposed tax, explores its challenges, and offers recommendations for successful implementation.

23 December 2021 in Medical Journal of Indonesia
Verified
Journal Article
Open access
PDF file
AKAyers Gilberth Ivano Kalaij
Ayers Gilberth Ivano Kalaij
VDValerie Josephine Dirjayanto
Valerie Josephine Dirjayanto
SYSyarif Maulana Yusuf
Syarif Maulana Yusuf
ENErni Juwita Nelwan
Erni Juwita Nelwan
BACKGROUND Despite various research on vaccine development, severe acute respiratory syndrome coronavirus 2 infection continues to spread. Thus, developing a more effective vaccine for production and clinical efficacy is still in high demand. This review aimed to assess the immunogenicity and safety of adenovirus-based vector vaccine (Ad-vaccines) including Ad5-vectored, ChAdOx1 nCoV-19, rAd26-S or rAd5-S, and Ad26.COV2.S as the promising solutions for COVID-19. METHODS We conducted a systematic review and meta analysis of clinical trials based on the preferred reporting items for systematic reviews and meta-analyses guidelines through PubMed, Scopus, Cochrane, and EBSCOhost until August 17, 2021. We implemented inclusion and exclusion criteria and assessed the studies using OHAT risk of bias rating tool for human and animal studies. Pooled estimates of odds ratio (OR) were analyzed using fixed-effect model. RESULTS This systematic review yielded 12 clinical studies with a total of 75,105 subjects. Although the studies were heterogeneous, this meta-analysis showed that Ad-vaccine significantly increased protection and immune response against COVID-19 with a pooled efficacy of 84.68% compared to placebo (p<0.00001). Forest plot also indicated that Ad-vaccine conferred protection against moderate to severe COVID-19 with a pooled OR of 0.26 (p<0.00001). Ad-vaccine had also shown a good safety profile with local site pain and fever as the most common side effects. CONCLUSIONS Ad-vaccine had shown a good immunogenicity for COVID-19 with a good pooled efficacy and was proven safe for COVID-19 patients.

21 April 2025 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
AKAyers Gilberth Ivano Kalaij
Ayers Gilberth Ivano Kalaij
MBMelani Limenco Benly
Melani Limenco Benly
RARuth Grace Aurora
Ruth Grace Aurora
TATaofan
Taofan
SISuci Indriani
Suci Indriani
SASuko Adiarto
Suko Adiarto
Introduction: Over the years, paclitaxel-coated balloons (PCBs) have been considered a standard treatment for femoropopliteal (FP) lesions due to their higher efficacy compared to noncoated balloon angioplasty. However, some studies have raised concerns about a potential link between PCBs and increased long-term mortality. Although relatively new, sirolimus is studied as an alternative that could be safer and more efficacious. Objective: This study aims to analyze the efficacy and safety of novel sirolimus-coated balloons (SCBs) for the treatment of femoropopliteal lesions. Materials and Methods: A literature search was conducted across PubMed, Scopus, Cochrane, Science Direct, and Google Scholar databases. Five single-arm trials met the predefined eligibility criteria for inclusion and were assessed using the ROBINS-I tool. Data extraction was followed by single-arm meta-analysis in RStudio with meta package software. Major Findings: Overall, a total of 5 single-arm trials were included. During 6-month follow-ups, SCBs have proven to have a high primary patency rate (pooled: 92%) and high freedom to target lesion revascularization (TLR) rates (pooled: 96%) with no heterogeneity ( I 2 = 0%). In terms of safety, the pooled incidence of clinically driven—target vessel revascularization (CD-TVR) is 1%, while pooled clinically driven—target lesion revascularization (CD-TLR) rate is 2%, pooled amputation rate is 3%, and pooled incidence of mortality was 1%. During 12-month follow-ups, SCBs have high primary patency rate (pooled: 87%), high freedom to TLR rates (pooled: 96%), low amputation rate (pooled: 3%), and pooled incidence of mortality was 4%. Conclusion: Novel SCB is efficacious and safe in treating femoropopliteal lesions and thus could be a prompt alternative in treating FP lesions, although further studies are still needed. Hopefully, this method could be a treatment option for FP disease in symptomatic patients. Clinical Impact: Sirolimus-coated balloons (SCBs) offer a promising alternative to paclitaxel-coated balloons (PCBs) for femoropopliteal lesions, demonstrating high efficacy with superior primary patency and low target lesion revascularization rates. The findings suggest SCBs may mitigate safety concerns associated with PCBs, potentially reducing long-term mortality risks. For clinicians, this innovation provides a safer, effective endovascular option, enhancing patient outcomes while maintaining procedural simplicity. With further validation, SCBs could redefine the standard of care for peripheral artery disease, ensuring optimal long-term vascular health with minimal complications.

23 January 2025 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
AKAyers Gilberth Ivano Kalaij
Ayers Gilberth Ivano Kalaij
SZSania Zahrani
Sania Zahrani
KSKeviano Bobby Saputro
Keviano Bobby Saputro
ASAverina Geffanie Suwana
Averina Geffanie Suwana
TATaofan
Taofan
SASuko Adiarto
Suko Adiarto